Ximena A Levander1, Jarratt D Pytell2, Kenneth B Stoller3, P Todd Korthuis1, Geetanjali Chander2,4. 1. Department of Medicine, Division of General Internal Medicine and Geriatrics, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, USA. 2. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 3. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
Background: In the United States, methadone for treatment of opioid use disorder is dispensed via highly-regulated accredited opioid treatment programs (OTP). During the COVID-19 pandemic, federal regulations were loosened, allowing for greater use of take-home methadone doses. We sought to understand how OTP leaders responded to these policy changes. Methods: We distributed a multistate electronic survey from September to November 2020 of OTP leadership to members of the American Association for the Treatment of Opioid Dependence (AATOD) who self-identified as leaders of OTPs. We asked study participants about how their OTP(s) implemented COVID-19-related policy changes into their clinical practice focusing on provision of take-home methadone doses, factors used to determine patient stability, and potential concerns about increased take-home doses. We used Chi-square test to compare survey responses between characterizations of the OTPs. Results: Of 170 survey respondents (17% response rate), the majority represented leadership of for-profit OTPs (69%) and were in a Southern state (54%). Routine allowances and practices related to take-home methadone doses varied across OTPs during the COVID-19 pandemic: 80 (47%) reported 14 days for newly enrolled patients (within past 90 days), 89 (52%) reported 14 days for "less stable" patients, and 112 (66%) reported 28 days for "stable" patients. Conclusions: We found that not all eligible OTP leaders adopted the practice of routinely allowing newly enrolled, "less stable," and "stable" patients on methadone to have increased take-home doses up to the limit allowed by federal regulations during COVID-19. The pandemic provides an opportunity to critically re-evaluate long-established methadone and OTP regulations in preparation for future emergencies.
Background: In the United States, methadone for treatment of opioid use disorder is dispensed via highly-regulated accredited opioid treatment programs (OTP). During the COVID-19 pandemic, federal regulations were loosened, allowing for greater use of take-home methadone doses. We sought to understand how OTP leaders responded to these policy changes. Methods: We distributed a multistate electronic survey from September to November 2020 of OTP leadership to members of the American Association for the Treatment of Opioid Dependence (AATOD) who self-identified as leaders of OTPs. We asked study participants about how their OTP(s) implemented COVID-19-related policy changes into their clinical practice focusing on provision of take-home methadone doses, factors used to determine patient stability, and potential concerns about increased take-home doses. We used Chi-square test to compare survey responses between characterizations of the OTPs. Results: Of 170 survey respondents (17% response rate), the majority represented leadership of for-profit OTPs (69%) and were in a Southern state (54%). Routine allowances and practices related to take-home methadone doses varied across OTPs during the COVID-19 pandemic: 80 (47%) reported 14 days for newly enrolled patients (within past 90 days), 89 (52%) reported 14 days for "less stable" patients, and 112 (66%) reported 28 days for "stable" patients. Conclusions: We found that not all eligible OTP leaders adopted the practice of routinely allowing newly enrolled, "less stable," and "stable" patients on methadone to have increased take-home doses up to the limit allowed by federal regulations during COVID-19. The pandemic provides an opportunity to critically re-evaluate long-established methadone and OTP regulations in preparation for future emergencies.
Authors: Margarita Alegría; Richard G Frank; Helena B Hansen; Joshua M Sharfstein; Ruth S Shim; Matt Tierney Journal: Health Aff (Millwood) Date: 2021-01-21 Impact factor: 6.301
Authors: Paul A Harris; Robert Taylor; Brenda L Minor; Veida Elliott; Michelle Fernandez; Lindsay O'Neal; Laura McLeod; Giovanni Delacqua; Francesco Delacqua; Jacqueline Kirby; Stephany N Duda Journal: J Biomed Inform Date: 2019-05-09 Impact factor: 6.317
Authors: Tara Gomes; Tonya J Campbell; Sophie A Kitchen; Ria Garg; Nikki Bozinoff; Siyu Men; Mina Tadrous; Charlotte Munro; Tony Antoniou; Dan Werb; Jennifer Wyman Journal: JAMA Date: 2022-03-01 Impact factor: 157.335
Authors: Yesenia Aponte-Melendez; Pedro Mateu-Gelabert; Chunki Fong; Benjamin Eckhardt; Shashi Kapadia; Kristen Marks Journal: Harm Reduct J Date: 2021-11-24
Authors: Ximena A Levander; Kim A Hoffman; John W McIlveen; Dennis McCarty; Javier Ponce Terashima; P Todd Korthuis Journal: Addict Sci Clin Pract Date: 2021-12-11
Authors: Anh Truc Vo; Thomas Patton; Amy Peacock; Sarah Larney; Annick Borquez Journal: Int J Environ Res Public Health Date: 2022-07-21 Impact factor: 4.614
Authors: Jordon D Bosse; Kim Hoffman; Katharina Wiest; P Todd Korthuis; Ritwika Petluri; Kellie Pertl; Stephen A Martin Journal: Addict Sci Clin Pract Date: 2022-09-09